杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/11/01 | 1,769 | 1,800 | 1,756 | 1,800 | +54 | +3.1% | 163,000 |
2021/10/29 | 1,760 | 1,761 | 1,738 | 1,746 | -16 | -0.9% | 95,000 |
2021/10/28 | 1,747 | 1,766 | 1,741 | 1,762 | +8 | +0.5% | 493,700 |
2021/10/27 | 1,764 | 1,779 | 1,746 | 1,754 | -7 | -0.4% | 201,600 |
2021/10/26 | 1,768 | 1,774 | 1,753 | 1,761 | -1 | -0.1% | 134,500 |
2021/10/25 | 1,793 | 1,798 | 1,754 | 1,762 | -33 | -1.8% | 130,000 |
2021/10/22 | 1,782 | 1,800 | 1,778 | 1,795 | -5 | -0.3% | 99,400 |
2021/10/21 | 1,806 | 1,808 | 1,794 | 1,800 | -10 | -0.6% | 84,400 |
2021/10/20 | 1,799 | 1,810 | 1,794 | 1,810 | +14 | +0.8% | 91,000 |
2021/10/19 | 1,790 | 1,806 | 1,782 | 1,796 | +4 | +0.2% | 65,300 |
2021/10/18 | 1,800 | 1,800 | 1,784 | 1,792 | -13 | -0.7% | 79,700 |
2021/10/15 | 1,767 | 1,805 | 1,762 | 1,805 | +32 | +1.8% | 89,100 |
2021/10/14 | 1,771 | 1,776 | 1,762 | 1,773 | +1 | +0.1% | 88,600 |
2021/10/13 | 1,778 | 1,786 | 1,771 | 1,772 | -6 | -0.3% | 69,000 |
2021/10/12 | 1,788 | 1,793 | 1,773 | 1,778 | -21 | -1.2% | 87,300 |
2021/10/11 | 1,782 | 1,799 | 1,775 | 1,799 | +17 | +1% | 92,500 |
2021/10/08 | 1,774 | 1,792 | 1,771 | 1,782 | +7 | +0.4% | 130,900 |
2021/10/07 | 1,760 | 1,784 | 1,760 | 1,775 | +4 | +0.2% | 74,700 |
2021/10/06 | 1,759 | 1,777 | 1,750 | 1,771 | +13 | +0.7% | 84,400 |
2021/10/05 | 1,766 | 1,772 | 1,748 | 1,758 | -20 | -1.1% | 98,600 |
2021/10/04 | 1,764 | 1,779 | 1,757 | 1,778 | +19 | +1.1% | 71,200 |
2021/10/01 | 1,768 | 1,776 | 1,751 | 1,759 | -22 | -1.2% | 81,200 |
2021/09/30 | 1,779 | 1,799 | 1,779 | 1,781 | +5 | +0.3% | 69,500 |
2021/09/29 | 1,786 | 1,786 | 1,763 | 1,776 | -43 | -2.4% | 107,500 |
2021/09/28 | 1,826 | 1,826 | 1,815 | 1,819 | -7 | -0.4% | 95,200 |
2021/09/27 | 1,860 | 1,860 | 1,825 | 1,826 | -40 | -2.1% | 90,800 |
2021/09/24 | 1,883 | 1,883 | 1,863 | 1,866 | +20 | +1.1% | 112,800 |
2021/09/22 | 1,857 | 1,857 | 1,844 | 1,846 | -16 | -0.9% | 88,600 |
2021/09/21 | 1,876 | 1,886 | 1,862 | 1,862 | -26 | -1.4% | 90,500 |
2021/09/17 | 1,892 | 1,895 | 1,882 | 1,888 | +1 | +0.1% | 131,400 |
2021/09/16 | 1,886 | 1,893 | 1,876 | 1,887 | +3 | +0.2% | 133,800 |
2021/09/15 | 1,883 | 1,890 | 1,879 | 1,884 | -16 | -0.8% | 63,200 |
2021/09/14 | 1,901 | 1,906 | 1,885 | 1,900 | -1 | -0.1% | 100,300 |
2021/09/13 | 1,879 | 1,901 | 1,867 | 1,901 | +20 | +1.1% | 77,600 |
2021/09/10 | 1,861 | 1,881 | 1,860 | 1,881 | +15 | +0.8% | 116,700 |
2021/09/09 | 1,866 | 1,877 | 1,860 | 1,866 | -5 | -0.3% | 60,500 |
2021/09/08 | 1,884 | 1,889 | 1,863 | 1,871 | -9 | -0.5% | 89,100 |
2021/09/07 | 1,878 | 1,885 | 1,870 | 1,880 | +14 | +0.8% | 98,800 |
2021/09/06 | 1,860 | 1,869 | 1,850 | 1,866 | -4 | -0.2% | 96,000 |
2021/09/03 | 1,850 | 1,873 | 1,846 | 1,870 | +29 | +1.6% | 102,900 |
2021/09/02 | 1,837 | 1,851 | 1,830 | 1,841 | +1 | +0.1% | 97,000 |
2021/09/01 | 1,830 | 1,843 | 1,821 | 1,840 | +17 | +0.9% | 81,700 |
2021/08/31 | 1,850 | 1,851 | 1,819 | 1,823 | -31 | -1.7% | 106,300 |
2021/08/30 | 1,832 | 1,854 | 1,828 | 1,854 | +27 | +1.5% | 77,500 |
2021/08/27 | 1,812 | 1,829 | 1,802 | 1,827 | +10 | +0.6% | 80,800 |
2021/08/26 | 1,827 | 1,827 | 1,810 | 1,817 | -10 | -0.5% | 68,100 |
2021/08/25 | 1,848 | 1,848 | 1,821 | 1,827 | -11 | -0.6% | 93,600 |
2021/08/24 | 1,843 | 1,853 | 1,833 | 1,838 | -15 | -0.8% | 104,400 |
2021/08/23 | 1,848 | 1,858 | 1,839 | 1,853 | +20 | +1.1% | 100,600 |
2021/08/20 | 1,844 | 1,849 | 1,828 | 1,833 | -9 | -0.5% | 116,600 |
751~
800
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム